Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × NSCLC × Docetaxel × Clear all

Phase

Status

Sponsor Class

OTHER 4 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 172 Breast Neoplasms 117 Prostatic Neoplasms 64 Neoplasms 54 Neoplasm Metastasis 45 Lung Neoplasms 41 Stomach Neoplasms 22 Parkinson Disease 4, Autosomal Dominant Lewy Body 17 Squamous Cell Carcinoma of Head and Neck 14 Ovarian Neoplasms 14 Advanced Solid Tumors 13 Recurrence 12 Urinary Bladder Neoplasms 11 Carcinoma, Squamous Cell 10 Melanoma 9 Head and Neck Neoplasms 9 Colorectal Neoplasms 9 Esophageal Neoplasms 8 Carcinoma, Renal Cell 8 Solid Tumor 7 Esophageal Squamous Cell Carcinoma 7 Carcinoma, Transitional Cell 7 Carcinoma 7 Triple Negative Breast Neoplasms 6 Pancreatic Neoplasms 6 Neutropenia 6 HER2-positive Breast Cancer 6 Endometrial Neoplasms 6 Sarcoma 5 Prostatic Neoplasms, Castration-Resistant 5

Interventions

aflutinib 5 Carboplatin 5 osimertinib 4 Pemetrexed 3 HM781-36B 3 Gefitinib 3 Paclitaxel 2 HMPL-013 2 Cisplatin 2 Albumin-Bound Paclitaxel 2 tipifarnib 1 sulindac sulfone 1 spartalizumab 1 rezivertinib 1 pembrolizumab 1 icotinib 1 aumolertinib 1 apatinib 1 Vinorelbine 1 Taxes 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Docetaxel 1 Clinical Trials, Phase I as Topic 1 Cetuximab 1 CP protocol 1 Bortezomib 1 BID protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05378763 2026-02-18

PINNACLE

Spectrum Pharmaceuticals, Inc

Phase 3 Suspended

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡